Ruth Carter retired from the Drug Enforcement Administration as a senior manager with over 30 years of experience as a diversion investigator, having worked at DEA headquarters and five field offices. While a DEA manager, she provided regulatory oversight of all regulatory compliance inspections and investigations of DEA registrants and civil and criminal investigations of pharmaceutical controlled substance diversion within her geographic region.
Ruth supervised the inspection and investigation of businesses that import, export, manufacture, distribute or dispense controlled substances and listed chemicals to ensure compliance with the Controlled Substances Act and its implementing regulations related to drug and facility security, recordkeeping, and accountability. These regulatory investigations included on-site investigations, such as specific reviews of operational and physical security controls and procedures employed at DEA-registered controlled substance manufacturing and distribution sites throughout the United States, and suspicious order monitoring systems, including the review of suspicious orders due diligence procedures.
Ruth Carter
Strategic Partner
Ruth Carter
Strategic Partner
Ruth Carter retired from the Drug Enforcement Administration as a senior manager with over 30 years of experience as a diversion investigator, having worked at DEA headquarters and five field offices. While a DEA manager, she provided regulatory oversight of all regulatory compliance inspections and investigations of DEA registrants and civil and criminal investigations of pharmaceutical controlled substance diversion within her geographic region.
Ruth supervised the inspection and investigation of businesses that import, export, manufacture, distribute or dispense controlled substances and listed chemicals to ensure compliance with the Controlled Substances Act and its implementing regulations related to drug and facility security, recordkeeping, and accountability. These regulatory investigations included on-site investigations, such as specific reviews of operational and physical security controls and procedures employed at DEA-registered controlled substance manufacturing and distribution sites throughout the United States, and suspicious order monitoring systems, including the review of suspicious orders due diligence procedures.